Zobrazeno 1 - 10
of 20
pro vyhledávání: '"C S, Higano"'
Autor:
C J, Pezaro, A, Omlin, K, Mastris, G, Attard, T M, Beer, K N, Chi, S, Chowdhury, I D, Davis, C G, Drake, J S, de Bono, E, Efstathiou, G, Gravis, C S, Higano, M, Hussain, N, James, C J, Logothetis, A, Morgans, C, Parker, C J, Ryan, F, Saad, O, Sartor, E J, Small, C N, Sternberg, C J, Sweeney, I, Tannock, B, Tombal, S, Gillessen
Publikováno v:
Annals of Oncology. 28:1692-1694
Autor:
Frederick R. Appelbaum, Motomi Mori, John A. Hansen, J. Nemunaitis, Rainer Storb, C. Epstein, James A. Bianco, C. S. Higano, Buckner Cd, E. D. Thomas, J. Lipani, J. W. Singer
Publikováno v:
Blood. 77:2065-2071
Forty-seven patients with hematologic neoplasia received recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) by daily 2-hour infusion following allogeneic bone marrow transplantation from HLA-identical sibling donors in a ph
Publikováno v:
Clinicalexperimental metastasis. 20(2)
Bisphosphonates (BisP) are non-metabolized compounds with high bone affinity used in bone metastasis diagnosis and treatment. Currently, BisP are used to treat hypercalcemia of malignancy as well as to prevent, minimize, or delay skeletal morbidity.
Autor:
A Y, Liu, L D, True, L, LaTray, W J, Ellis, R L, Vessella, P H, Lange, C S, Higano, L, Hood, G, van den Engh
Publikováno v:
The Prostate. 40(3)
Prostate tumor heterogeneity as manifested by differential expression of markers can be attributed to multiple types of cancer cells populating a tumor. Does the composition differ between primary tumor and metastasis? How can one isolate the differe
Autor:
C S, Higano, D, Chielens, W, Raskind, E, Bryant, M E, Flowers, J, Radich, R, Clift, F, Appelbaum
Publikováno v:
Blood. 90(7)
Fourteen patients with cytogenetic relapse of chronic myeloid leukemia (CML) after transplantation with unmanipulated bone marrow were treated with alpha-2a-interferon. There were eight men and six women, median age, 33 years. Twelve patients receive
Publikováno v:
Journal of Clinical Oncology. 29:4655-4655
4655 Background: Many patients with biochemical relapse after definitive therapy for prostate cancer receive androgen deprivation therapy. PSA levels eventually will rise despite castrate levels of...
Autor:
L. Klotz, C. J. O'Callaghan, K. Ding, D. P. Dearnaley, C. S. Higano, E. M. Horwitz, S. Malone, S. L. Goldenberg, M. K. Gospodarowicz, J. M. Crook
Publikováno v:
Journal of Clinical Oncology. 29:3-3
3 Background: In men with PSA recurrence after radical radiotherapy (RRT), intermittent androgen suppression (IAS) has been suggested by phase II trials to improve quality of life (QoL) but effects on survival are unknown. In this Intergroup randomiz
Publikováno v:
Journal of Clinical Oncology. 29:135-135
135 Background: Many patients with biochemical relapse after definitive therapy for prostate cancer receive androgen deprivation therapy. Although most patients experience a decline in PSA, PSA eventually rises despite a castrate level of testosteron
Publikováno v:
Journal of Clinical Oncology. 28:4558-4558
4558 Background: Androgen deprivation therapy (ADT) for prostate cancer leads to loss of bone mineral density (BMD) and increased fracture risk. We hypothesize that intermittent ADT (IADT) may atte...
Autor:
E. J. Small, T. M. Beer, V. K. Weinberg, C. S. Higano, L. T. Nordquist, J. E. Rosenberg, J. J. Alumkal, E. Y. Yu, J. Sun, A. M. Lin
Publikováno v:
Journal of Clinical Oncology. 28:4684-4684